| Previous Close | 7.20 |
| Open | 6.28 |
| Bid | 7.05 x 200 |
| Ask | 7.42 x 200 |
| Day's Range | 6.26 - 6.26 |
| 52 Week Range | 4.60 - 7.49 |
| Volume | 188 |
| Avg. Volume | 16,295 |
| Market Cap | 99.51M |
| Beta | 0.53 |
| PE Ratio (TTM) | -14.23 |
| EPS (TTM) | -0.44 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- PR Newswire•2 hours ago
Cumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention
NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.
- Simply Wall St.•12 days ago
What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?
If you are a shareholder in Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT
Q2 2017 Cumberland Pharmaceuticals Inc Earnings Call
